跳至主要内容
临床试验/NCT00650390
NCT00650390Approved For Marketing不适用

Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab

Abbott0 个研究点开始时间: 2008年4月1日最近更新:
适应症

试验速览

阶段
不适用
状态
Approved For Marketing
发起方
Abbott

研究概览

简要总结

The study was to explore the efficacy of adalimumab in subjects previously treated with infliximab and failed infliximab treatment due to lack of efficacy or intolerance. To explore the safety of adalimumab in subjects previously treated with infliximab.

研究设计

研究类型
Expanded Access

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Males and females >= 18 years of age
  • ACR criteria for RA diagnosis for at least 6 months
  • Active RA defined as a DAS 28 >3.2 at study entry
  • Unsatisfactory response, loss of response or intolerance to prior infliximab treatment
  • A negative pregnancy test for females of childbearing potential

排除标准

  • Patient who had previous treatment with cyclophosphamide and chlorambucil
  • Treatment within the last 8 weeks with infliximab
  • Prior treatment with more than one DMARD or DMARD combination following infliximab treatment
  • Prior treatment with biologics (Investigational or Commercial) RA therapies other than infliximab
  • History of cancer, other than successfully treated squamous cell or basal cell carcinoma or lymphoproliferative disease
  • Prior treatment with total lymphoid irradiation

研究者

发起方
Abbott
申办方类型
Industry

相似试验